Topic: Raptiva
Psoriasis is a common skin condition that causes skin redness and irritation. Inverse - Skin redness and irritation occurs in the armpits, groin, and in between overlapping skin. The following may trigger an attack of psoriasis or make the condition more difficult ...
On the European Commission granted a marketing authorisation valid throughout the European Union for the medicinal product Raptiva (efalizumab), indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have ...
LONDON, 8 June 2009--The European Medicines Agency has agreed to an EU-wide recall of all of the remaining batches of Raptiva, from Merck Serono. Following this, the medicine will no longer be available anywhere in the European Union.. In May 2009, Merck ...
BioTrends Group today released its syndicated report TreatmentTrends(R): On April 8th, 2009, Genentech and Roche announced the voluntary withdrawal of Raptiva from the U.S. market. Among the Dermatologists surveyed, 41% had patients on Raptiva at the time of the announcement, but only ...
Genentech, the company that makes Raptiva (efalizumab) to treat psoriasis, recently announced it has begun a voluntary, phased withdrawal of the drug from the U.S. market because it has the potential to cause progressive multifocal leukoencephalopathy (PML), a rare, progressive neurological disease ...
The Food and Drug Administration announced a recall of the psoriasis drug Raptiva yesterday because the drug may lead to an incurable, debilitating and potentially deadly brain infection. At that time the FDA said it would undertake a risk analysis to determine ...
-Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market. Prescribers should immediately begin discussing with patients currently using Raptiva on how to transition to alternative ...
The troubled psoriasis drug Raptiva is being withdrawn from the U.S. market, California-based drug maker Genentech announced Wednesday.. In a prepared release, Genentech said Wednesday, "Effective immediately, physicians should not issue prescriptions for Raptiva for any new patients and should promptly contact ...
Genentech, Inc. announced today a phased voluntary withdrawal of the psoriasis drug Raptiva (efalizumab) from the U.S. market. Effective immediately, physicians should not issue prescriptions for Raptiva for any new patients and should promptly contact patients currently receiving Raptiva to assess the ...
[UPDATE 04/08/2009] Genentech and FDA notified healthcare professionals of the voluntary, phased withdrawal of Raptiva, a medication for treatment of psoriasis, from the U.S. market due to a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML). [Posted 02/19/2009] FDA issued ...
From Around the Web
Video Gallery
-
Psoriasis Drug Raptiva Recalled Due To ...
Genentech is conducting a phased market withdrawal of the psoriasis ...2009-10-12 -
Serious Infections and Neurological Events with ...
FDA is highlighting the risk of life-threatening infections in patients ...2009-01-14 -
New Raptiva TV Ad / AudetLaw.com
Raptiva allegedly causes a number of serious life-threatening infections, including ...2010-03-22
